Next Article in Journal
Chromosomics: Bridging the Gap between Genomes and Chromosomes
Previous Article in Journal
Viral Sequences Detection by High-Throughput Sequencing in Cerebrospinal Fluid of Individuals with and without Central Nervous System Disease
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Role of MIR9-2 in Shared Susceptibility of Psychiatric Disorders during Childhood: A Population-Based Birth Cohort Study

by
Luciana Tovo-Rodrigues
1,*,
Gabriela Callo Quinte
1,
Clarice Brinck Brum
1,
Gabriele Ghisleni
2,
Clarissa Ribeiro Bastos
2,
Isabel Oliveira de Oliveira
1,
Fernando C. Barros
1,3,
Aluisio J. D. Barros
1,
Iná S. Santos
1,4,
Luis A. Rohde
5,6,
Mara H. Hutz
7 and
Alicia Matijasevich
8
1
Postgraduate Program in Epidemiology, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul 96020-220, Brazil
2
Laboratory of Clinical Neuroscience, Post-Graduate Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul 96015-560, Brazi
3
Postgraduate Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul 96015-560, Brazil
4
Post-graduate Program Pediatrics Child Health, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90619-900, Brazil
5
Department of Psychiatry, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90035-007, Brazil
6
National Institute of Developmental Psychiatry for Children and Adolescents, São Paulo, São Paulo 05403-900, Brazil
7
Program in Genetics and Molecular Biology Universidade Federal do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul 91501-970, Brazil
8
Departamento de Medicina Preventiva, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, 01246-903, Brasil
*
Author to whom correspondence should be addressed.
Genes 2019, 10(8), 626; https://doi.org/10.3390/genes10080626
Submission received: 26 May 2019 / Revised: 23 July 2019 / Accepted: 13 August 2019 / Published: 20 August 2019
(This article belongs to the Section Human Genomics and Genetic Diseases)

Abstract

:
Background: It has been suggested that microRNAs (miRNAs; short non-protein-coding RNA molecules that mediate post-transcriptional regulation), including mir-9 and mir-34 families, are important for brain development. Current data suggest that mir-9 and mir-34 may have shared effects across psychiatric disorders. This study aims to explore the role of genetic polymorphisms in the MIR9-2 (rs4916723) and MIR34B/C (rs4938723) genes on the susceptibility of psychiatric disorders in children from the 2004 Pelotas Birth Cohort. Methods: Psychiatric disorders were assessed in 3585 individuals using Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), criteria through the application of standard semi-structured interviews (using the Development and Well-Being Assessment, DAWBA) at the six-years-of-age follow-up. The outcome was defined as the presence of any mental disorder. We also considered two broad groups of internalizing and externalizing disorders to further investigate the role of these variants in mental health. Results: We observed an association between rs4916723 (MIR9-2) and the presence of any psychiatric disorder (odds ratios (OR) = 0.820; 95% CI = 0.7130–0.944; p = 0.006) and a suggestive effect on internalizing disorders (OR = 0.830; 95% CI = 0.698–0.987; p = 0.035). rs4938723 (MIR34B/C) was not associated with any evaluated outcome. Conclusion: The study suggests that MIR9-2 may have an important role on a broad susceptibility for psychiatric disorders and may be important mainly for internalization problems.

1. Introduction

Psychiatric disorders with a childhood or adolescence onset are known to persist throughout life [1,2]. They are prevalent disorders with moderate to high genetic components, according to classic genetic evidences [3,4,5,6]. Shared symptoms and substantial epidemiological comorbidity incite debates about the extension of etiologic overlap. It has been shown that psychiatric disorders broadly share common genetic risk variants, mostly with neurodevelopmental effects [7], suggesting that current clinical boundaries do not reflect distinct underlying pathogenic processes, at least on the genetic level [7,8].
Dysregulation of complex gene networks in the developing brain is thought to underlie many of these disorders [9]. A growing body of evidence demonstrates that microRNAs (miRNAs), defined as short non-protein-coding RNA molecules that mediate post-transcriptional regulation by affecting miRNA stability and translation [10,11], play an important role on epigenetic regulation in brain functions and plasticity [12]. In fact, using the brain samples deposited on the Alen BrainSpan Atlas of the developing human brain, Ziats and Rennert (2014) [13] presented a spatio-temporal assessment of miRNA expression throughout early human brain development. The authors demonstrated that a set of miRNAs is differentially expressed along the brain development, suggesting that these molecules play critical roles in transcriptional networks of the developing human brain and neurodevelopmental disorders. miRNA-related genetic polymorphisms could potentially affect the maturation, expression, and structure of miRNAs, as well as their base pairing at the target site. It may, then, have a functional role in miRNA-mediated gene regulation, thereby affecting psychiatric diseases [14,15]. The role of miRNAs on psychiatric disorders has been explored in previous studies [16].
Among the miRNAs with described roles in the brain, mir-9 and mir-34 expressed transcript families are the most studied and have the greatest known relevance for brain processes. The gene MIR9-2 is one of the genomic loci of the mir-9 family, whose relevance in neurogenesis has been extensively explored. Its role in the regulation of genes and pathways involved in differentiation of neural stem cells [17,18], proliferation and migration of neural progenitor cells [19], regulation of dopaminergic signaling [20], synaptic plasticity, and hippocampus-dependent memory [21] have been reported. In humans, mir-9 was observed to be differentially expressed in the hippocampus from infancy to early childhood [13], showing its importance for brain development processes. Alterations of the mir-9 expression in brain [22] and blood [23] tissues of patients with schizophrenia, in brain of Alzheimer’s disease patients [24], and the up-regulation in Parkinson’s disease treated patients compared to the untreated and the control groups [25] were observed, reinforcing its important role in the normal brain functions and development. In humans, MIR9-2, or its transcript expression, was already associated with schizophrenia [26], attention deficit and hyperactivity disorder (ADHD) [27], and neuroticism [28], and a pleiotropic effect across disorders has been reported [29]. rs4916723, placed about 108 kb downstream the MIR9-2 gene, has already been associated with ADHD [27], with a set of psychiatric disorders [29], neuroticism [28], and alcohol consumption [30], and it was nominally associated with the autism spectrum disorder [31].
In mammals, the mir-34 family consists of three members, mir-34a, mir-34b, and mir-34c [32]. Together, the mir-34 family members are important regulators of neuronal development, plasticity, and disease. The proposed function of mir-34 family on neural stem cell differentiation, neurite elongation, neuronal differentiation, regulation of cell proliferation, and synaptogenesis has been reported [33,34]. rs4938723, placed in the MIR34B/C cluster promoter region, has been shown to modulate the expression of both genes [35]. It was already associated with major depression [36]. The mir-9 and mir-34 expression share a temporal profile, being differentially expressed in different brain regions from infancy (4 months–1 year) to early childhood (2–4 years) [13].
The elucidation of genetic influences and mechanisms shared across disorders may have an important impact on drug development, psychiatric nosology, and risk prediction. Considering the importance of miRNA-mediated gene regulation in brain development, it is expected that their effect emerges early in the susceptibility to psychiatric diseases. Although the relevance of mir-9 and mir-34 in several psychiatry disorders has been reported in the literature, to the best of our knowledge, their effects were not tested in populational-based studies where several disorders might be diagnosed. This study aims to explore the role of polymorphisms of the genes MIR9-2 (rs4916723) and MIR34B/C (rs4938723) on the susceptibility of psychiatric disorders among children belonging to the 2004 Pelotas Birth Cohort study.

2. Methods

The present investigation uses data from the 2004 Pelotas birth cohort, a population-based study in the southern Brazilian city of Pelotas. Mothers of 4231 children accepted to participate in the study (refuses <1%) and were included in the study. So far, these children have been followed up at the ages of 3 and 12 months, 2, 4, 6, and 11 years, with follow-up rates of 95.7%, 94.3%, 93.5%, 92.0%, 90.2%, and 86.6%, respectively [37,38]. The present study used data from the perinatal assessment and the 6-year follow-up. At this follow-up (mean age: 6.6 years old, SD: 0.20), the children underwent a wide-range health assessment with interviews, including a saliva sample collection for DNA extraction [38]. The Oragene-250 kit model (DNA Genotek®, Ontario, Canada) was used for sample collection. DNA extraction was performed according to the manufacturer’s instructions. Only singleton children were included in this study.

2.1. Mental Health Outcomes

The psychiatric disorder diagnosis was obtained using the Development and Well-Being Assessment (DAWBA) [39], an instrument that consists of a structured part and open-ended questions about symptoms of psychiatric disorders, having questions based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), diagnosis [40]. We used the Portuguese-language version of the DAWBA, which has been cross-culturally adapted and validated for use in Brazil [41]. The DAWBA was administered to mothers or caregivers by trained psychologists. More details can be found elsewhere [38,40].
At age 6, a total of 3585 (84.7% of 4231 births) children were assessed using DAWBA. Nearly 13% of the children presented any psychiatric disorder, according to DSM-IV. Anxiety disorders were the most prevalent (8.8%), followed by attention-deficit/hyperactivity disorders (ADHD, 2.6%), oppositional defiant disorder/conduct disorder (ODD/CD, 2.6%), and depression (1.3%). Autism (0.3%), Tic disorder and Tourette Syndrome (0.4%), eating disorders (0.03%), and stereotypies (0.1%) were also diagnosed [40].
We considered the presence of any of the mental disorders mentioned above as the main outcome in this study. We also aimed to explore the association between the polymorphisms and internalization/externalization disorders. We classified the disorders in two broad groups, as done by others [42]: Internalizing (comprised by any anxiety and depressive disorders) and externalizing (ADHD and ODD/CD) disorders.

2.2. Genetic Polymorphisms and Genotyping

Two polymorphisms were investigated: rs4916723, placed in chromosome 5, about 108 kb downstream to the MIR9-2 gene (GRCh37 assembly), and rs4938723, placed in chromosome 11, about 1.1 kb and 1.6 kb upstream to MIR34B/C genes, respectively (GRCh37 assembly). Considering the relevance of the MIR9-2 and MIR34B/C genes for brain development, the choice of polymorphisms around the genes was based on (1) results from studies about psychiatric disorders and related traits exploring the rs4916723 [27,28,29,30,31] and the rs4938723 [35,36], (2) minor allelic frequencies (MAF) in European and African continental populations higher than 0.10, and (3) technical viability (probes already designed and standardized by the manufacturer). The polymorphisms were genotyped using Taqman single nucleotide polymorphism (SNP) genotyping assays (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s recommended protocol for the allelic discrimination system (7500 Real Time PCR System, Applied Biosystems, Foster City, CA, USA).

2.3. Statistical Analyses

Allele and genotypic frequencies were estimated by counting. The Hardy–Weinberg equilibrium (HWE) was estimated through a chi-square test and implemented in the 1.9 PLINK software [43,44]. The threshold for the significance of HWE departure was set at 0.025, considering the adjustment for two tests (Bonferroni correction). In order to estimate the effect of individual markers, binary logistic regression was performed, using an additive genetic model and the major allele as the reference. The estimates are given through odds ratios (OR), 95% confidence intervals, and p-values. The analyses were performed using Stata v 14.0 (Stata LP, College Station, YX, USA).
For the association analysis, the alfa was corrected for multiple tests using the Bonferroni approach. The significant results were those with a p value lower than 0.008 (6 tests). Those tests comprising p-values between 0.008 and 0.05 were considered as suggestive associations. The adjusted regression model included skin color (white, brown, black, and others) and sex as confounders. As a sensitivity analysis, to minimize the possible effect of the environmental factors involving child-mother relationship, we run a model including maternal depression assessed by the Edinburgh Postnatal Depression Scale (EPDS) when the children were one year old. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

2.4. In Silico Functionality Analysis

In order to provide further information about the putative regulatory function of each marker included in this study, we assessed HaploReg v4.1 [45]. It is a tool for exploring annotations of the noncoding genome in variants. Information on the chromatin state and protein binding annotation from the Roadmap Epigenomics and The Encyclopedia of DNA Elements (ENCODE) projects are functional evidences integrated in this dataset.

2.5. Ethics Approval and Consent to Participate

The School of Medicine Research Ethics Committee of the Federal University of Pelotas approved the study protocol and all follow-ups of the Pelotas 2004 Birth Cohort Study (ID 40870314.2.0000.5317). Informed consent was obtained from the guardians (mother, father, or legal guardian) of all participants, who signed the informed consent form.

3. Results

At the 6-year follow-up, a total of 3447 individuals had mental health information and valid genotypes for rs4916723 and 3425 subjects for rs4938723. Amongst included participants, approximately 52% of the subjects were male, 68% had white skin color, and 43% of the mothers had studied for nine or more years. Table 1 shows the demographic and health characteristics of the probands included in the study and the genotypic frequency distribution for the two SNPs. Included and non-included participants had similar frequencies of boys and girls, skin color classification groups, and mother schooling. On the other hand, children included in the present analyses had lower frequencies of poorest and richest participants (according to the wealth index).
The minor allele frequencies were 0.368 (C-allele) for rs4916723 and 0.339 (C-allele) for rs4938723. No polymorphisms departed from the Hardy–Weinberg equilibrium (p = 0.15 for rs4916723, p = 0.04 for rs4938723).
Table 2 shows the association estimates for each polymorphism considering the presence of at least one psychiatric disorder considering DMS-IV diagnosis criteria for crude and adjusted models. The logistic regression using the additive model showed an association between rs4916723 (MIR9-2) and the presence of any psychiatric disorders after adjustment (odds ratios (OR) = 0.820; 95% CI = 0.713–0.944; p = 0.006). A protective effect of allele C was observed.
When the disorders were classified as internalizing or externalizing, a suggestive protective effect of allele C was observed for the internalizing group (OR = 0.830; 95% CI = 0.698–0.987; p = 0.035). For the externalizing group, the effect size was a little smaller and no association was observed. No association was observed for rs4938723 (MIR34B/C), both with the presence of any psychiatric disorder and for the test, including internalizing/externalizing subgroups. Similar results were found when we ran a model adjusting for maternal depression assessed in one year old children (Table S1).
In silico analysis was performed to explore the potential regulatory function of the investigated variants. The rs4916723 site is located in an intronic region of the LINC00461 gene. According to HaploReg data, it is placed in a region of the promoter and enhances marks in the brain. It is also considered an expression quantitative trait loci (eQTL) for LINC02060 in the same tissue (Table 3). Considering the regulatory regions specific in the brain, this SNP is placed in active domains of chromatin (Table 4), which are active sites (based on the Roadmap Epigenomics Consortium 15 chromatin state model) related to promoter and enhancer region for the fetal brain tissues, which is also confirmed by the DNAse hypersensitive sites. Moreover, the Roadmap Epigenomics Consortium 25 chromatin state model suggests that this SNP may play a role in adult brains as well (Table 4).
Considering the rs4938723 site, the elusive functional regulatory function in the brain was observed. However, histone marks were observed in other tissues (Table 3).

4. Discussion

In this study, we investigated the role of SNPs near the genes MIR9-2 and MIR34B/C on mental health outcomes among children in a population-based Brazilian cohort. Our results suggest that rs4916723, close to the MIR9-2, has an important effect in the development of mental disorders, and more specifically in internalizing disorders. The findings are supported by the regulatory function of this SNP in the brain.
In this study, we observed an association between rs4916723 and the presence of any psychiatric disorders in childhood. Recent genome-wide association studies (GWAS studies) have indicated an important role of rs4916723 on several psychiatric diseases and related traits. A risk effect of the C-allele was already reported for ADHD in the most recent meta-analysis [27] as well as for several mental disorders (i.e., anorexia nervosa, ADHD, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome) in a cross-psychiatric disorder meta-analysis of 232,964 cases and 494,162 controls [29]. A suggestive risk effect of the same allele was shown in the most recent autism spectrum disorder GWAS meta-analysis [31]. On the other hand, a protective effect of the same allele was already observed for alcohol consumption [30], neuroticism [28], which are phenotypes related to psychiatric disorders (Table S2). The latter are in agreement with the Brazilian findings. These findings reinforce its relevance in psychiatric disorders and they strengthen the need for further studies exploring the role of this marker on mental health. Differences in the mental disorders evaluated, age of assessment, and genetic background may explain the difference between the findings regarding the direction. Anxiety disorders was the most prevalent disorder in our study; however, they were not included in the published meta-analysis. Our sample included only children, while the meta-analysis included adults as well. The differences in the population background may also play a role on this divergence.
Our findings also suggest that the association considering rs4916723 may be specially related with internalizing disorders. Neuroticism, which may be defined as a tendency to experience negative emotions and high stress reactivity, has been pointed as an important factor for mood and anxiety, being suggested as the core feature for internalizing psychopathologies [46,47,48,49]. rs4916723 was also associated with neuroticism in a recent meta-analysis, in the same direction as our results, as mentioned above [28]. This role in neuroticism is in accordance with our suggestive association with internalizing disorders.
Although rs4916723 is close to MIR9-2, its function on the gene remains to be elucidated. This SNP is placed in the gene LINC00461, a non-coding RNA that is up-regulated in the brain [50], but without an established brain-specific role until the date. The MIR9-2 gene is encoded on the same strand in the 3’ end of three splice forms of LINC00461 [50], and the knockdown of LINC00461 also drastically suppressed expression levels of mir-9, explicating the relation between both genes and providing the potential link between rs4916723 and MIR9-2. It is possible that this SNP is in linkage disequilibrium with other markers, leading to an indirect association with psychiatric disorders in our study. An important regulatory effect on the brain for rs4916723 is shown by HaploReg v.4.1 [45] data. The effect of this SNP in MIR9-2 and the function of specific alleles on regulatory effects deserve further evaluation.
In our study, we did not observe a significant effect of MIR34B/C in the evaluated outcomes, contrasting with the results observed in ADHD [35] and depression [36] so far. rs4938723, in the MIR34B/C cluster promoter region, has been shown to modulate the expression of both genes and has an impact on the expression levels of genes regulated by both miRNA, including genes previously associated with ADHD and the central nervous system [38]. Mir-34b was observed to be differentially expressed in the dorsolateral prefrontal cortex and in the ventrolateral prefrontal cortex from infancy (4 months–1 year) to early childhood (2–4 years) [13]. Mir-34c was also differentially expressed in the dorsolateral prefrontal cortex from infancy to early childhood. The association considering this polymorphism should be addressed in future studies.
Our results must be interpreted in the context of some limitations. There were small differences between the extreme socioeconomic groups of the included and not included participants. However, the response rate was high, which helps attenuate possible selection bias. Regarding the externalizing/internalizing tests, it is important to note that the size effect for the externalizing group was a little smaller, with a wide confidence interval. Although an important effect on internalizing disorders was observed, we cannot exclude the hypothesis that this polymorphism may also play a role on externalizing. Further studies should address this topic. On the other hand, our findings were identified from a majority-white population, and our results may not be generalizable to populations with other ethnic backgrounds. Although results from the city of Pelotas do not indicate population stratification in the region [51] and the allelic effect is similar in white and non-white individuals in our samples, we are not able to rule out populational stratification potential bias, since we do not have the population genomic. Moreover, given the small prevalence of psychiatric disorders at the age of six, it was not possible to consider every single diagnosed disorder, which would benefit the disease-specificity effect exploration of the SNPs included in this study.

5. Conclusions

Finally, to the best of our knowledge, this is the first study exploring the role of MIR9-2 and the MIR43B/C cluster on mental health susceptibility in a large population-based cohort. The study suggests that MIR9-2 may have an important role on a broad susceptibility for psychiatric disorders, mainly those related with internalization. It also shows the need for other studies to better understand the extension of shared genetic effects in psychiatric diseases.

Supplementary Materials

The following are available online at https://www.mdpi.com/2073-4425/10/8/626/s1, Table S1: Association analysis between SNPs and mental health outcomes at 6 years of age using logistic regression (crude and adjusted models) and additive genetic model. The adjusted model includes the correction for maternal depression. Table S2: Summary of recent GWAS findings regarding rs4916723 on psychiatric disorders and related traits.

Author Contributions

L.T.-R. conceived the work. L.T.-R., G.C.Q., C.B.B., G.G., and C.R.B. conducted the analyses. L.T.-R., G.C.Q., and C.B.B. drafted the first version of the manuscript. I.S.S., A.M., A.J.D.B., G.G., and F.C.B. made substantial contributions to the acquisition and interpretation of data. I.S.S., A.M., A.J.D.B., G.G., C.R.B., I.O.d.O., F.C.B., A.J.D.B., L.A.R., and M.H.H. revised the manuscript critically and contributed with interpretation of the findings. All authors gave final approval of the version to be published.

Funding

This work was supported by Wellcome Trust from 2009 to 2013. The World Health Organization, National Support Program for Centers of Excellence (PRONEX), Brazilian National Research Council (CNPq), Brazilian Ministry of Health, and Children’s Pastorate supported previous phases of the study. This article is based on data from the study “Pelotas Birth Cohort, 2004”, conducted by the Postgraduate Program in Epidemiology at Universidade Federal de Pelotas, with the collaboration of the Brazilian Public Health Association (ABRASCO). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. It was also funded by the Research Support Foundation of Rio Grande do Sul—FAPERGS (Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul), grant 16/2551-0000374-2–Fapergs/CNPq 08/2014. Luciana Tovo-Rodrigues, Gabriele Ghisleni, Fernando C. Barros, Aluisio J.D. Barros, Iná S. Santos, Luis A. Rohde, Mara H. Hutz and Alicia Matijasevich, are suported by the CNPq.

Conflicts of Interest

Luis Augusto Rohde was on the speakers’ bureau/advisory board and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Medice, and Shire in the last three years. He receives authorship royalties from Oxford Press and ArtMed. He also received a travel award for taking part in the 2015 WFADHD meeting from Shire. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Rohde received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire.

References

  1. De Girolamo, G.; Dagani, J.; Purcell, R.; Cocchi, A.; McGorry, P.D. Age of Onset of Mental Disorders and Use of Mental Health Services: Needs, Opportunities and Obstacles. Epidemiol. Psychiatr. Sci. 2012, 21, 47–57. [Google Scholar] [CrossRef]
  2. Kessler, R.C.; Amminger, G.P.; Aguilar-Gaxiola, S.; Alonso, J.; Lee, S.; Ustün, T.B. Age of Onset of Mental Disorders: A Review of Recent Literature. Curr. Opin. Psychiatry 2007, 20, 359–364. [Google Scholar] [CrossRef]
  3. Domschke, K.; Maron, E. Genetic Factors in Anxiety Disorders. Mod. Trends Pharmacopsychiatry 2013, 29, 24–46. [Google Scholar] [PubMed]
  4. Faraone, S.V.; Larsson, H. Genetics of Attention Deficit Hyperactivity Disorder. Mol. Psychiatry 2019, 24, 562–575. [Google Scholar] [CrossRef] [PubMed]
  5. Sandin, S.; Lichtenstein, P.; Kuja-Halkola, R.; Hultman, C.; Larsson, H.; Reichenberg, A. The Heritability of Autism Spectrum Disorder. JAMA 2017, 318, 1182–1184. [Google Scholar] [CrossRef] [PubMed]
  6. Sullivan, P.F.; Neale, M.C.; Kendler, K.S. Genetic Epidemiology of Major Depression: Review and Meta-Analysis. Am. J. Psychiatry 2000, 157, 1552–1562. [Google Scholar] [CrossRef]
  7. Anttila, V.; Bulik-Sullivan, B.; Finucane, H.K.; Walters, R.K.; Bras, J.; Duncan, L.; Escott-Price, V.; Falcone, G.J.; Gormley, P.; Malik, R.; et al. Analysis of Shared Heritability in Common Disorders of the Brain. Science 2018, 360, 8757. [Google Scholar]
  8. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic Relationship between Five Psychiatric Disorders Estimated from Genome-Wide Snps. Nat. Genet. 2013, 45, 984–994. [Google Scholar] [CrossRef] [PubMed]
  9. Li, M.; Santpere, G.; Imamura Kawasawa, Y.; Evgrafov, O.V.; Gulden, F.O.; Pochareddy, S.; Sunkin, S.M.; Li, Z.; Shin, Y.; Zhu, Y.; et al. Integrative Functional Genomic Analysis of Human Brain Development and Neuropsychiatric Risks. Science 2018, 362, eaat7615. [Google Scholar] [CrossRef]
  10. Filipowicz, W.; Bhattacharyya, S.N.; Sonenberg, N. Mechanisms of Post-Transcriptional Regulation by Micrornas: Are the Answers in Sight? Nat. Rev. Genet. 2008, 9, 102–114. [Google Scholar] [CrossRef] [PubMed]
  11. Vasudevan, S.; Tong, Y.C.; Steitz, J.A. Switching from Repression to Activation: Micrornas Can up-Regulate Translation. Science 2007, 318, 1931–1934. [Google Scholar] [CrossRef] [PubMed]
  12. Forero, D.A.; van der Ven, K.; Callaerts, P.; Del-Favero, J. Mirna Genes and the Brain: Implications for Psychiatric Disordersa. Hum. Mutat. 2010, 31, 1195–1204. [Google Scholar] [CrossRef] [PubMed]
  13. Ziats, M.N.; Rennert, O.M. Identification of Differentially Expressed Micrornas across the Developing Human Brain. Mol. Psychiatry 2014, 19, 848–852. [Google Scholar] [CrossRef] [PubMed]
  14. Alural, B.; Genc, S.; Haggarty, S.J. Diagnostic and Therapeutic Potential of Micrornas in Neuropsychiatric Disorders: Past, Present, and Future. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2017, 73, 87–103. [Google Scholar] [CrossRef] [PubMed]
  15. Mishra, P.J.; Mishra, P.J.; Banerjee, D.; Bertino, J.R. Mirsnps or Mir-Polymorphisms, New Players in Microrna Mediated Regulation of the Cell: Introducing Microrna Pharmacogenomics. Cell Cycle 2008, 7, 853–858. [Google Scholar] [CrossRef] [PubMed]
  16. Issler, O.; Chen, A. Determining the Role of Micrornas in Psychiatric Disorders. Nat. Rev. Neurosci. 2015, 16, 201–212. [Google Scholar] [CrossRef] [PubMed]
  17. Saunders, L.R.; Sharma, A.D.; Tawney, J.; Nakagawa, M.; Okita, K.; Yamanaka, S.; Willenbring, H.; Verdin, E. Mirnas Regulate Sirt1 Expression During Mouse Embryonic Stem Cell Differentiation and in Adult Mouse Tissues. Aging 2010, 2, 415–431. [Google Scholar] [CrossRef]
  18. Zhao, C.N.; Sun, G.Q.; Li, S.X.; Shi, Y.H. A Feedback Regulatory Loop Involving Microrna-9 and Nuclear Receptor Tlx in Neural Stem Cell Fate Determination. Nat. Struct. Mol. Biol. 2009, 16, 365–371. [Google Scholar] [CrossRef]
  19. Delaloy, C.; Liu, L.; Lee, J.A.; Su, H.; Shen, F.X.; Yang, G.Y.; Young, W.L.; Ivey, K.N.; Gao, F.B. Microrna-9 Coordinates Proliferation and Migration of Human Embryonic Stem Cell-Derived Neural Progenitors. Cell Stem Cell 2010, 6, 323–335. [Google Scholar] [CrossRef]
  20. Shi, S.; Leites, C.; He, D.; Schwartz, D.; Moy, W.; Shi, J.X.; Duan, J.B. Microrna-9 and Microrna-326 Regulate Human Dopamine D2 Receptor Expression, and the Microrna-Mediated Expression Regulation Is Altered by a Genetic Variant. J. Biol. Chem. 2014, 289, 13434–13444. [Google Scholar] [CrossRef]
  21. Sim, S.E.; Lim, C.S.; Kim, J.I.; Seo, D.; Chun, H.; Yu, N.K.; Lee, J.; Kang, S.J.; Ko, H.G.; Choi, J.H. The Brain-Enriched Microrna Mir-9-3p Regulates Synaptic Plasticity and Memory. J. Neurosci. 2016, 36, 8641–8652. [Google Scholar] [CrossRef] [PubMed]
  22. Perkins, D.O.; Jeffries, C.D.; Jarskog, L.F.; Thomson, J.M.; Woods, K.; Newman, M.A.; Parker, J.S.; Jin, J.; Hammond, S.M. Microrna Expression in the Prefrontal Cortex of Individuals with Schizophrenia and Schizoaffective Disorder. Genome Biol. 2007, 8, R27. [Google Scholar] [CrossRef] [PubMed]
  23. Camkurt, M.A.; Karababa, F.; Erdal, M.E.; Bayazıt, H.; Kandemir, S.B.; Ay, M.E.; Kandemir, H.; Ay, Ö.İ.; Çiçek, E.; Selek, S.; et al. Investigation of Dysregulation of Several Micrornas in Peripheral Blood of Schizophrenia Patients. Clin. Psychopharmacol. Neurosci. 2016, 14, 256–260. [Google Scholar] [CrossRef] [PubMed]
  24. Miya Shaik, M.; Tamargo, I.A.; Abubakar, M.B.; Kamal, M.A.; Greig, N.H.; Gan, S.H. The Role of Micrornas in Alzheimer’s Disease and Their Therapeutic Potentials. Genes 2018, 9, 174. [Google Scholar] [CrossRef]
  25. Alieva, A.K.; Filatova, E.V.; Karabanov, A.V.; Illarioshkin, S.N.; Limborska, S.A.; Shadrina, M.I.; Slominsky, P.A. Mirna Expression Is Highly Sensitive to a Drug Therapy in Parkinson’s Disease. Parkinsonism Relat. Disord. 2015, 21, 72–74. [Google Scholar] [CrossRef] [PubMed]
  26. Topol, A.; Zhu, S.J.; Hartley, B.J.; English, J.; Hauberg, M.E.; Tran, N.; Rittenhouse, C.A.; Simone, A.; Ruderfer, D.M.; Johnson, J.; et al. Dysregulation of Mirna-9 in a Subset of Schizophrenia Patient-Derived Neural Progenitor Cells. Cell Rep. 2016, 15, 1024–1036. [Google Scholar] [CrossRef]
  27. Demontis, D.; Walters, R.K.; Martin, J.; Mattheisen, M.; Als, T.D.; Agerbo, E.; Baldursson, G.; Belliveau, R.; Bybjerg-Grauholm, J.; Bækvad-Hansen, M. Discovery of the First Genome-Wide Significant Risk Loci for Attention Deficit/Hyperactivity Disorder. Nat. Genet. 2019, 51, 63–75. [Google Scholar] [CrossRef]
  28. Nagel, M.; Jansen, P.R.; Stringer, S.; Watanabe, K.; de Leeuw, C.A.; Bryois, J.; Savage, J.E.; Hammerschlag, A.R.; Skene, N.G.; Muñoz-Manchado, A.B. Meta-Analysis of Genome-Wide Association Studies for Neuroticism in 449,484 Individuals Identifies Novel Genetic Loci and Pathways. Nat. Genet. 2018, 50, 920–927. [Google Scholar] [CrossRef]
  29. Lee, P.H.; Anttila, V.; Won, H.; Feng, Y.-C.A.; Rosenthal, J.; Zhu, Z.; Tucker-Drob, E.M.; Nivard, M.G.; Grotzinger, A.D.; Posthuma, D.; et al. Genome Wide Meta-Analysis Identifies Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. bioRxiv 2019, 528117. [Google Scholar] [CrossRef]
  30. Liu, M.; Jiang, Y.; Wedow, R.; Li, Y.; Brazel, D.M.; Chen, F.; Datta, G.; Davila-Velderrain, J.; McGuire, D.; Tian, C.; et al. Association Studies of up to 1.2 Million Individuals Yield New Insights into the Genetic Etiology of Tobacco and Alcohol Use. Nat. Genet. 2019, 51, 237–244. [Google Scholar] [CrossRef]
  31. Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; Andreassen, O.A.; Anney, R.; et al. Identification of Common Genetic Risk Variants for Autism Spectrum Disorder. Nat. Genet. 2019, 51, 431–444. [Google Scholar] [CrossRef] [PubMed]
  32. Hermeking, H. The Mir-34 Family in Cancer and Apoptosis. Cell Death Differ. 2009, 17, 193–199. [Google Scholar] [CrossRef] [PubMed]
  33. Jauhari, A.; Yadav, S. Mir-34 and Mir-200: Regulator of Cell Fate Plasticity and Neural Development. NeuroMolecular Med. 2019, 21, 97–109. [Google Scholar] [CrossRef] [PubMed]
  34. Banerjee-Basu, S.; Larsen, E.; Muend, S. Common Micrornas Target Established Asd Genes. Front. Neurol. 2014, 5, 205. [Google Scholar] [CrossRef] [PubMed]
  35. Garcia-Martínez, I.; Sánchez-Mora, C.; Pagerols, M.; Richarte, V.; Corrales, M.; Fadeuilhe, C.; Cormand, B.; Casas, M.; Ramos-Quiroga, J.A.; Ribasés, M. Preliminary Evidence for Association of Genetic Variants in Pri-Mir-34b/C and Abnormal Mir-34c Expression with Attention Deficit and Hyperactivity Disorder. Transl. Psychiatry 2016, 6, e879. [Google Scholar] [CrossRef]
  36. Xu, C.; Yang, C.; Zhang, A.; Xu, Y.; Li, X.; Liu, Z.; Liu, S.; Sun, N.; Zhang, K. The Interaction of Mir-34b/C Polymorphisms and Negative Life Events Increases Susceptibility to Major Depressive Disorder in Han Chinese Population. Neurosci. Lett. 2017, 651, 65–71. [Google Scholar] [CrossRef]
  37. Santos, I.S.; Barros, A.J.D.; Matijasevich, A.; Domingues, M.R.; Barros, F.C.; Victora, C.G. Cohort Profile: The 2004 Pelotas (Brazil) Birth Cohort Study. Int. J. Epidemiol. 2010, 40, 1461–1468. [Google Scholar] [CrossRef] [Green Version]
  38. Santos, I.S.; Barros, A.J.; Matijasevich, A.; Zanini, R.; Chrestani Cesar, M.A.; Camargo-Figuera, F.A.; Oliveira, I.O.; Barros, F.C.; Victora, C.G. Cohort Profile Update: 2004 Pelotas (Brazil) Birth Cohort Study. Body Composition, Mental Health and Genetic Assessment at the 6 Years Follow-Up. Int. J. Epidemiol. 2014, 43, 1437. [Google Scholar] [CrossRef]
  39. Goodman, R.; Ford, T.; Richards, H.; Gatward, R.; Meltzer, H. The Development and Well-Being Assessment: Description and Initial Validation of an Integrated Assessment of Child and Adolescent Psychopathology. J. Child Psychol. Psychiatry Allied Discip. 2000, 41, 645–655. [Google Scholar] [CrossRef]
  40. Petresco, S.; Anselmi, L.; Santos, I.S.; Barros, A.J.; Fleitlich-Bilyk, B.; Barros, F.C.; Matijasevich, A. Prevalence and Comorbidity of Psychiatric Disorders among 6-Year-Old Children: 2004 Pelotas Birth Cohort. Soc. Psychiatry Psychiatr. Epidemiol. 2014, 49, 975–983. [Google Scholar] [CrossRef]
  41. Fleitlich-Bilyk, B.; Goodman, R. Prevalence of Child and Adolescent Psychiatric Disorders in Southeast Brazil. J. Am. Acad. Child Adolesc. Psychiatry 2004, 43, 727–734. [Google Scholar] [CrossRef] [PubMed]
  42. Matijasevich, A.; Murray, J.; Cooper, P.J.; Anselmi, L.; Barros, A.J.; Barros, F.C.; Santos, I.S. Trajectories of Maternal Depression and Offspring Psychopathology at 6 Years: 2004 Pelotas Cohort Study. J. Affect. Disord. 2015, 174, 424–431. [Google Scholar] [CrossRef] [PubMed]
  43. Chang, C.C.; Chow, C.C.; Tellier, L.C.; Vattikuti, S.; Purcell, S.M.; Lee, J.J. Second-Generation Plink: Rising to the Challenge of Larger and Richer Datasets. Gigascience 2015, 4, 7. [Google Scholar] [CrossRef] [PubMed]
  44. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.; Daly, M.J.; et al. Plink: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am. J. Hum. Genet. 2007, 81, 559–575. [Google Scholar] [CrossRef] [PubMed]
  45. Ward, L.D.; Kellis, M. Haploreg: A Resource for Exploring Chromatin States, Conservation, and Regulatory Motif Alterations within Sets of Genetically Linked Variants. Nucleic Acids Res. 2012, 40, D930–D9344. [Google Scholar] [CrossRef] [PubMed]
  46. Griffith, J.W.; Zinbarg, R.E.; Craske, M.G.; Mineka, S.; Rose, R.D.; Waters, A.M.; Sutton, J.M. Neuroticism as a Common Dimension in the Internalizing Disorders. Psychol. Med. 2010, 40, 1125–1136. [Google Scholar] [CrossRef]
  47. Hettema, J.M.; Neale, M.C.; Myers, J.M.; Prescott, C.A.; Kendler, K.S. A Population-Based Twin Study of the Relationship between Neuroticism and Internalizing Disorders. Am. J. Psychiatry 2006, 163, 857–864. [Google Scholar] [CrossRef] [PubMed]
  48. Kendler, K.S.; Myers, J. The Genetic and Environmental Relationship between Major Depression and the Five-Factor Model of Personality. Psychol. Med. 2009, 40, 801–806. [Google Scholar] [CrossRef]
  49. Middeldorp, C.M.; Cath, D.C. The Association of Personality with Anxious and Depressive Psycopathology. In Biology of Personal and Individual Differences; Canli, T., Ed.; Guilford Press: New York, NY, USA; London, UK, 2006; pp. 251–272. [Google Scholar]
  50. Smith, R.M.; Webb, A.; Papp, A.C.; Newman, L.C.; Handelman, S.K.; Suhy, A.; Mascarenhas, R.; Oberdick, J.; Sadee, W. Whole Transcriptome Rna-Seq Allelic Expression in Human Brain. BMC Genom. 2013, 14, 571. [Google Scholar] [CrossRef]
  51. Lima-Costa, M.F.; Rodrigues, L.C.; Barreto, M.L.; Gouveia, M.; Horta, B.L.; Mambrini, J.; Kehdy, F.S.; Pereira, A.; Rodrigues-Soares, F.; Victora, C.G.; et al. Genomic Ancestry and Ethnoracial Self-Classification Based on 5871 Community-Dwelling Brazilians (the Epigen Initiative). Sci. Rep. 2015, 5, 9812. [Google Scholar] [CrossRef]
Table 1. Socio demographic characteristics and genotype frequencies distribution among the participants of the 2004 Pelotas birth cohort.
Table 1. Socio demographic characteristics and genotype frequencies distribution among the participants of the 2004 Pelotas birth cohort.
VariablesIncluded (n = 3447)Not included (n = 784)p-Value
Sexn (%)n (%)
Male1780 (51.6)415 (52.9)0.513
Female1667 (48.4)369 (47.1)
Skin color 0.137
White2332 (67.7)394 (71.4)
Black428 (12.4)54 (9.8)
Others686 (19.9)104 (18.8)
Mother schooling (y) 0.057
<5512 (15.0)142 (18.4)
5–81426 (41.7)305 (39.6)
>91478 (43.3)323 (42.0)
Wealth Index (quintiles) 0.001
1st (poorest)579 (20.9)128 (25.6)
2nd523 (18.9)97 (19.4)
3rd551 (19.9)84 (16.8)
4th576 (20.8)74 (14.8)
5th (richest)536 (19.5)117 (23.4)
Genotypes *
rs4916723
AA1356 (39.3)-
AC1644 (47.7)-
CC447 (13.0)-
rs4938723
TT1522 (44.5)-
CT1482 (43.3)-
CC420 (12.2)-
* rs4916723 Hardy–Weinberg equilibrium (HWE): p-value: Chi-square = 2.18, p = 0.140; rs4938723 chi-square = 4.03, p-value: 0.045.
Table 2. Association analysis between single nucleotide polymorphisms (SNPs) and mental health outcomes at six years of age using logistic regression (crude and adjusted models) and an additive genetic model.
Table 2. Association analysis between single nucleotide polymorphisms (SNPs) and mental health outcomes at six years of age using logistic regression (crude and adjusted models) and an additive genetic model.
Outcomenrs4916723 (MIR9-2) ORcrude (95% CI)rs4916723 (MIR9-2) * ORadj (95% CI)* padjNrs4938723 (MIR34B/C) ORcrude (95% CI)rs4938723 (MIR34B/C) * ORadj (95% CI)* padj
Effect Allele: C Effect Allele: C
Any disorder34470.816 (0.710–0.938)0.820 (0.713–0.944)0.00634241.047 (0.915–1.198)1.055 (0.921–1.208)0.442
Any externalizing disorder34470.863 (0.672–1.108)0.870 (0.676–1.118)0.27634241.063 (0.835–1.353)1.074 (0.843–1.368)0.566
Any internalizing disorder34470.824 (0.693–0.979)0.830 (0.698–0.987)0.03534240.994 (0.841–1.176)1.002 (0.847–1.185)0.984
* Regression model adjusted by skin color and sex. Sample size post adjustment: 3446 for rs4916723 and 3424 for rs4938723. N = Sample size included in the crude models. Internalizing disorders comprise any depressive and anxiety disorders. Externalizing disorders comprise attention deficit and hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and conduct disorder (CD). The significant and suggestive results are denoted in bold.
Table 3. Single nucleotide polymorphism (SNP) regulatory information available in Haploreg v4.1.
Table 3. Single nucleotide polymorphism (SNP) regulatory information available in Haploreg v4.1.
SNP IDCHRPosition (GRCh37)Gene/LocationPromoter Histone Marks TissuesEnhancer Histone Marks TissuesDNAse TissuesMotifs ChangedeQTL Hits
rs4916723587854395LINC00461 intronicBRNBRN, ESC, iPSC, BRN.CRTXBRN11 altered motifsLINC02060 in Brain Hippocampus and Nucleus accumbens
rs493872311111382565BTG4 intronicESC, BRSTESC, iPSC, FAT.ADIP, SKIN.PEN.FRSK.,BRST, SKIN.NHEKiPSC, BRST3 altered motifsCOLCA2 in Colon Transverse PPP2R1B in Whole Blood
Chromosome (CHR); Expression quantitative trait loci (eQTL); brain (BRN); embryonic stem cells (ESC); induced pluripotent stem cells (iPSC); adipose-derived mesenchymal stem cell cultured cells (FAT.ADIP); foreskin fibroblast primary cells (SKIN); foreskin melanocyte primary cells (SKIN.PEN.FRSK); Breast (BRST) epidermal Keratinocyte Primary Cells (SKIN.NHEK); Cortex-derived primary cultured neurospheres (BRN.CRTX). Long intergenic non-protein coding RNA 461 (LINC00461); BTG anti-proliferation factor 4 (BTG4); long intergenic non-protein coding RNA 2060 (LINC02060); colorectal cancer associated 2 (COLCA2); protein phosphatase 2 scaffold subunit Abeta (PPP2R1B): Search conducted on 18 May 2019.
Table 4. Regulatory sites in brain regions available for the two evaluated SNPs (HaploReg v4.1).
Table 4. Regulatory sites in brain regions available for the two evaluated SNPs (HaploReg v4.1).
Epigenome ID (EID)GroupDescriptionChromatin states (Core 15-State Model)Chromatin States (25-State Model Using 12 Imputed Marks)H3K4me1H3K4me3H3K27acH3K9acDNase
rs4916723
E071BrainBrain Hippocampus Middle-22_PromPH3K4me1_EnhH3K4me3_Pro---
E074BrainBrain Substantia Nigra--H3K4me1_EnhH3K4me3_Pro---
E068BrainBrain Anterior Caudate-22_PromPH3K4me1_EnhH3K4me3_Pro-H3K9ac_Pro-
E069BrainBrain Cingulate Gyrus-17_EnhW2------
E072BrainBrain Inferior Temporal Lobe--H3K4me1_Enh----
E067BrainBrain Angular Gyrus-19_DNaseH3K4me1_EnhH3K4me3_Pro---
E073BrainBrain_Dorsolateral_Prefrontal_Cortex-17_EnhW2 H3K4me3_ProH3K27ac_EnhH3K9ac_Pro-
E070BrainBrain Germinal Matrix2_TssAFlnk16_EnhW1H3K4me1_EnhH3K4me3_Pro- --
E082BrainFetal Brain Female2_TssAFlnk13_EnhA1H3K4me1_EnhH3K4me3_Pro- -DNase
E081BrainFetal Brain Male7_Enh16_EnhW1H3K4me1_Enh-- -DNase
rs4938723
E071BrainBrain Hippocampus Middle---H3K4me3_ProH3K27ac_Enh --
E074BrainBrain Substantia Nigra----H3K27ac_EnhH3K9ac_Pro-
E068BrainBrain Anterior Caudate---H3K4me3_ProH3K27ac_EnhH3K9ac_Pro-
E069BrainBrain Cingulate Gyrus--H3K4me1_EnhH3K4me3_ProH3K27ac_Enh--
E072BrainBrain Inferior Temporal Lobe---H3K4me3_Pro-H3K9ac_Pro-
E067BrainBrain Angular Gyrus--H3K4me1_EnhH3K4me3_Pro-H3K9ac_Pro-
E073BrainBrain_Dorsolateral_Prefrontal_Cortex-------
E070BrainBrain Germinal Matrix-------
E082BrainFetal Brain Female-------
E081BrainFetal Brain Male-------

Share and Cite

MDPI and ACS Style

Tovo-Rodrigues, L.; Quinte, G.C.; Brum, C.B.; Ghisleni, G.; Bastos, C.R.; Oliveira, I.O.d.; Barros, F.C.; Barros, A.J.D.; Santos, I.S.; Rohde, L.A.; et al. The Role of MIR9-2 in Shared Susceptibility of Psychiatric Disorders during Childhood: A Population-Based Birth Cohort Study. Genes 2019, 10, 626. https://doi.org/10.3390/genes10080626

AMA Style

Tovo-Rodrigues L, Quinte GC, Brum CB, Ghisleni G, Bastos CR, Oliveira IOd, Barros FC, Barros AJD, Santos IS, Rohde LA, et al. The Role of MIR9-2 in Shared Susceptibility of Psychiatric Disorders during Childhood: A Population-Based Birth Cohort Study. Genes. 2019; 10(8):626. https://doi.org/10.3390/genes10080626

Chicago/Turabian Style

Tovo-Rodrigues, Luciana, Gabriela Callo Quinte, Clarice Brinck Brum, Gabriele Ghisleni, Clarissa Ribeiro Bastos, Isabel Oliveira de Oliveira, Fernando C. Barros, Aluisio J. D. Barros, Iná S. Santos, Luis A. Rohde, and et al. 2019. "The Role of MIR9-2 in Shared Susceptibility of Psychiatric Disorders during Childhood: A Population-Based Birth Cohort Study" Genes 10, no. 8: 626. https://doi.org/10.3390/genes10080626

APA Style

Tovo-Rodrigues, L., Quinte, G. C., Brum, C. B., Ghisleni, G., Bastos, C. R., Oliveira, I. O. d., Barros, F. C., Barros, A. J. D., Santos, I. S., Rohde, L. A., Hutz, M. H., & Matijasevich, A. (2019). The Role of MIR9-2 in Shared Susceptibility of Psychiatric Disorders during Childhood: A Population-Based Birth Cohort Study. Genes, 10(8), 626. https://doi.org/10.3390/genes10080626

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop